Direkt zum Inhalt
Merck

Headaches as a presenting symptom of linear morphea en coup de sabre.

Pediatrics (2014-11-19)
Ingrid Polcari, Amanda Moon, Erin F Mathes, Elaine S Gilmore, Amy S Paller
ZUSAMMENFASSUNG

Linear morphea en coup de sabre (ECDS) is a form of localized scleroderma that predominantly affects the pediatric population, with a median age of 10 years at presentation. The existence of neurologic findings in association with ECDS has been well described in the literature. Here we describe 4 patients with ECDS who presented with headaches, which were typical migraines in 3 of the patients. The headaches preceded the onset of cutaneous findings by at least 6 months. Our patients' cases emphasize both the importance of recognizing headaches as a harbinger of ECDS and the necessity of performing thorough cutaneous examination in patients with unexplained headaches or other neurologic disease.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
L-Amethopterin Hydrat, ≥98% (HPLC), powder
USP
Prednison, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Prednison, ≥98%
Sigma-Aldrich
L-Amethopterin Hydrat, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
Methotrexat, meets USP testing specifications
SAFC
Methotrexat
Supelco
Methotrexat, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Prednison, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Methotrexat -Lösung, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexat, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Amethopterin Hydrat, ≥99.0% (sum of enantiomers, HPLC)
Methotrexat für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Methotrexat für die Systemeignung, European Pharmacopoeia (EP) Reference Standard